Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 267

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 11
Chunk 267
---
 party transactions. In general, the Audit
Committee will review any proposed transaction that has been identified as a related person transaction under Item 404 of Regulation
S-K, which means a transaction, arrangement or relationship in which we and any related person (as defined below) are participants in
which the amount involved exceeds the lesser of $120,000 or one percent of the average of the Company’s total assets at fiscal
year-end for the last two completed fiscal years, and in which any related person had, has or will have a direct or indirect material
interest. A “related person” includes (i) a director, director nominee or executive officer of the Company, (ii) any immediate
family member of the foregoing, or (iii) a security holder known to be a beneficial owner of more than 5% of any class of our voting
securities.

Other
than the compensation agreements and other arrangements described under “Executive Compensation” and the transactions described
below, since January 1, 2022, there has not been and there is not currently proposed, any transaction or series of similar transactions
to which we were, or will be, a participant in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average
of our total assets at December 31, 2023 and 2022, as applicable) and in which any related person, had, or will have, a direct or indirect
material interest.

Participation
in 2024 Financings

August
2024 Financing

On
August 8, 2024, we completed a registered direct offering, pursuant to which we sold and issued to certain investors 1,643,837 shares
of our common stock. In addition, in a concurrent private placement, we issued to the investors unregistered warrants to purchase 1,643,837
shares of our common stock. The warrants are immediately exercisable at an exercise price of $1.70 per share and expire five years from
the date of issuance. The combined purchase price for one share of common stock and one warrant was $1.825, resulting in gross proceeds
of approximately $3.0 million, before deducting placement agent and other offering expenses in the amount of approximately $0.5 million.
One of the purchasers was Jeffrey Meckler, our Chief Executive Officer and director, who purchased 84,932 shares of common stock and
warrants to purchase 84